Proactive Investors - Run By Investors For Investors

ImmuPharma continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus

The firm said that following the conclusion of the pivotal Phase III trial earlier in 2018, it continues to look at opportunities which, over the longer term, have the potential of bringing Lupuzor to market
Clinical trials
ImmuPharma also said discussions are continuing on the clinical development collaboration for its Nucant Cancer Programme

ImmuPharma PLC (LON:IMM) continues to engage with potential corporate partners for Lupuzor, its late-stage treatment for Lupus, as well as progressing potential collaboration opportunities on its other projects.

In a brief corporate update, the AIM-listed specialist drug discovery and development company said that, following the conclusion of the pivotal Phase III trial earlier in 2018, it continues to look at opportunities which, over the longer term, have the potential of bringing Lupuzor to market.

READ: ImmuPharma says article shines light on potential of peptide subsidiary

The company noted that, together with its partner, it is in the final preparations for the Lupuzor Managed Access Program which will be open to eligible patients in Europe, with further updates to be provided to the market in due course.

It added that the Lupuzor open-label extension study, from the original Phase III trial, with a total of 62 eligible patients recruited throughout the US and Europe, remains on track to report results in the second quarter of 2019.

Nucant Cancer Programme

Turning to other areas of development, ImmuPharma said discussions are continuing on the clinical development collaboration for its Nucant Cancer Programme with - as announced on 31 December 2018 - the exclusivity period having been extended to 31 March 2019, and an update will be provided in due course.

With regards to its Bordeaux based subsidiary, Ureka SARL – which is focusing on transforming peptides into efficient drugs for treatments in a number of therapeutic areas including Type II diabetes - ImmuPharma said continues to look at all options regarding the progression of Ureka's assets.

The firm said this process is ongoing and further updates will be announced as appropriate.

Tim McCarthy, ImmuPharma's chairman said: "We remain focused on creating long term value throughout our portfolio through initiatives including the Managed Access Program for Lupuzor,  whilst the Company continues to engage with industry partners for potential collaboration opportunities on its projects."

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives
eye
November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use